Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: FDA OKs IntelligentMDx C. Difficile Abbott m2000 Assay

Premium

IntelligentMDx said today that it has received US Food and Drug Administration clearance for its IMDx C. difficile for Abbott m2000 assay, a test that detects nucleic acids encoding the toxin A gene and toxin B gene sequences of toxigenic strains of Clostridium difficile in human stool specimens.

IMDx's analytical reactivity studies have demonstrated that its C. difficile assay is capable of detecting 31 different strains representing the global diversity of C. difficile, including NAP1 and tcdB variants.

C. difficile is the leading cause of hospital-acquired diarrhea and is linked to approximately 14,000 deaths in the United States annually, the company said.

IMDx's C. difficile assay is the company's third to receive FDA clearance in the last three months for use on Abbott's fully-automated m2000 system— following the IMDx VanR for Abbott m2000 and IMDx Flu A/B and RSV for Abbott m2000 assays (PCR 9/12/2013)

IMDx has a multi-year distribution agreement with Abbott encompassing a broad real-time PCR test menu designed, developed and manufactured for use on the m2000 system (PCR 3/17/2011).

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.